These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38052366)

  • 1. Delayed identification of treatment failure causes high levels of acquired drug resistance and less future drug options among HIV-1-infected South Indians.
    Sivamalar S; Gomathi S; Boobalan J; Balakrishnan P; Pradeep A; Devaraj CA; Solomonl SS; Nallusamy D; Nalini D; Sureka V; Saravanan S
    Indian J Med Microbiol; 2024; 47():100520. PubMed ID: 38052366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
    Ayitewala A; Kyeyune F; Ainembabazi P; Nabulime E; Kato CD; Nankya I
    AIDS Res Ther; 2020 Jan; 17(1):2. PubMed ID: 32005262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.
    Skhosana L; Steegen K; Bronze M; Lukhwareni A; Letsoalo E; Papathanasopoulos MA; Carmona SC; Stevens WS
    PLoS One; 2015; 10(2):e0118145. PubMed ID: 25659108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic HIV-1 Drug Resistance Among Patients Failing Tenofovir-Based First-Line HAART in South India.
    Dinesha TR; Gomathi S; Boobalan J; Sivamalar S; Solomon SS; Pradeep A; Poongulali S; Solomon S; Balakrishnan P; Saravanan S
    AIDS Res Hum Retroviruses; 2016 Dec; 32(12):1234-1236. PubMed ID: 27334566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon.
    Takou D; Fokam J; Teto G; Santoro MM; Ceccherini-Silberstein F; Nanfack AJ; Sosso SM; Dambaya B; Salpini R; Billong SC; Gori C; Fokunang CN; Cappelli G; Colizzi V; Perno CF; Ndjolo A
    BMC Infect Dis; 2019 Mar; 19(1):246. PubMed ID: 30871487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa.
    Chimukangara B; Lessells RJ; Singh L; Grigalionyte I; Yende-Zuma N; Adams R; Dawood H; Dlamini L; Buthelezi S; Chetty S; Diallo K; Duffus WA; Mogashoa M; Hagen MB; Giandhari J; de Oliveira T; Moodley P; Padayatchi N; Naidoo K
    AIDS Res Ther; 2021 Oct; 18(1):74. PubMed ID: 34656129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
    Liu P; Liao L; Xu W; Yan J; Zuo Z; Leng X; Wang J; Kan W; You Y; Xing H; Ruan Y; Shao Y
    Medicine (Baltimore); 2018 Dec; 97(50):e13555. PubMed ID: 30558015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.
    Gibson RM; Nickel G; Crawford M; Kyeyune F; Venner C; Nankya I; Nabulime E; Ndashimye E; Poon AFY; Salata RA; Kityo C; Mugyenyi P; Quiñones-Mateu ME; Arts EJ
    Infect Dis Poverty; 2017 Dec; 6(1):163. PubMed ID: 29202874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.
    Van Zyl GU; Liu TF; Claassen M; Engelbrecht S; de Oliveira T; Preiser W; Wood NT; Travers S; Shafer RW
    PLoS One; 2013; 8(6):e67188. PubMed ID: 23840622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study.
    Asare K; Sookrajh Y; van der Molen J; Khubone T; Lewis L; Lessells RJ; Naidoo K; Sosibo P; van Heerden R; Garrett N; Dorward J
    Lancet Glob Health; 2024 Feb; 12(2):e282-e291. PubMed ID: 38142692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries.
    Inzaule SC; Jordan MR; Cournil A; Girón-Callejas A; Avila-Rios S; Mulenga L; Ssemwanga D; Asio J; Diop-Ndiaye H; Niasse-Traore F; Nhan DT; Dat VQ; Aghokeng AF; Billong S; Cham F; Doherty M; Bertagnolio S;
    AIDS; 2020 Nov; 34(13):1965-1969. PubMed ID: 32694410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological outcomes of Tenofovir versus Zidovudine-based regimens among people living with HIV/AIDS: a two years retrospective cohort study.
    Ayele T; Jarso H; Mamo G
    AIDS Res Ther; 2017 Feb; 14(1):5. PubMed ID: 28143541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of tenofovir, zidovudine, or stavudine as part of first-line antiretroviral therapy in a resource-limited-setting: a cohort study.
    Velen K; Lewis JJ; Charalambous S; Grant AD; Churchyard GJ; Hoffmann CJ
    PLoS One; 2013; 8(5):e64459. PubMed ID: 23691224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
    Steegen K; Levin L; Evans D; Technau KG; Hans L
    Pediatr Infect Dis J; 2022 Oct; 41(10):827-834. PubMed ID: 35895893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.
    von Wyl V; Yerly S; Böni J; Shah C; Cellerai C; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Ledergerber B; Günthard HF;
    Clin Infect Dis; 2012 Jan; 54(1):131-40. PubMed ID: 22057700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India.
    Karade SK; Ghate MV; Chaturbhuj DN; Kadam DB; Shankar S; Gaikwad N; Gurav S; Joshi R; Sane SS; Kulkarni SS; Kurle SN; Paranjape RS; Rewari BB; Gangakhedkar RR
    Medicine (Baltimore); 2016 Sep; 95(37):e4886. PubMed ID: 27631260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
    Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
    AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.